Your browser doesn't support javascript.
loading
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics.
Valdeolivas, Alberto; Amberg, Bettina; Giroud, Nicolas; Richardson, Marion; Gálvez, Eric J C; Badillo, Solveig; Julien-Laferrière, Alice; Túrós, Demeter; Voith von Voithenberg, Lena; Wells, Isabelle; Pesti, Benedek; Lo, Amy A; Yángüez, Emilio; Das Thakur, Meghna; Bscheider, Michael; Sultan, Marc; Kumpesa, Nadine; Jacobsen, Björn; Bergauer, Tobias; Saez-Rodriguez, Julio; Rottenberg, Sven; Schwalie, Petra C; Hahn, Kerstin.
Afiliação
  • Valdeolivas A; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. alberto.valdeolivas_urbelz@roche.com.
  • Amberg B; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Giroud N; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Richardson M; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Gálvez EJC; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Badillo S; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Julien-Laferrière A; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Túrós D; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Voith von Voithenberg L; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Wells I; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Pesti B; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Lo AA; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Yángüez E; Genentech, Inc, San Francisco, CA, USA.
  • Das Thakur M; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Bscheider M; Genentech, Inc, San Francisco, CA, USA.
  • Sultan M; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Kumpesa N; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Jacobsen B; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Bergauer T; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Saez-Rodriguez J; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Rottenberg S; Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Heidelberg University, Heidelberg, Germany.
  • Schwalie PC; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Hahn K; Bern Center for Precision Medicine (BCPM), University of Bern, Bern, Switzerland.
NPJ Precis Oncol ; 8(1): 10, 2024 Jan 10.
Article em En | MEDLINE | ID: mdl-38200223
ABSTRACT
The consensus molecular subtypes (CMS) of colorectal cancer (CRC) is the most widely-used gene expression-based classification and has contributed to a better understanding of disease heterogeneity and prognosis. Nevertheless, CMS intratumoral heterogeneity restricts its clinical application, stressing the necessity of further characterizing the composition and architecture of CRC. Here, we used Spatial Transcriptomics (ST) in combination with single-cell RNA sequencing (scRNA-seq) to decipher the spatially resolved cellular and molecular composition of CRC. In addition to mapping the intratumoral heterogeneity of CMS and their microenvironment, we identified cell communication events in the tumor-stroma interface of CMS2 carcinomas. This includes tumor growth-inhibiting as well as -activating signals, such as the potential regulation of the ETV4 transcriptional activity by DCN or the PLAU-PLAUR ligand-receptor interaction. Our study illustrates the potential of ST to resolve CRC molecular heterogeneity and thereby help advance personalized therapy.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article